Studies Aim to Confirm Safety and Efficacy of Novel Bio-inspired Clot-dissolving Therapy
Cambridge, Mass., October 30, 2019 -- Thrombolytic Science, LLC (TSI) today announced progress with 10 patients enrolled in its prospective, randomized, multicenter Phase 2 clinical trial, designed to confirm the safety and efficacy of the sequential dual-treatment regimen of low-dose tissue plasminogen activator (tPA) and HisproUK (TSI’s mutant prourokinase [proUK]) in 200 ischemic stroke patients. The clinical trial is led by Prof. Diederik Dippel, MD, PhD, co-director of the Erasmus MC Stroke Center in Rotterdam, The Netherlands.
TSI also announced it has finalized the protocol for a multicenter Phase 2 study in 100 patients with myocardial infarction (MI), or heart attack. The Phase 2 MI trial will start enrolling patients in Ukraine the first half of 2020.
“We are on track with initiation and recruitment for both of our Phase 2 clinical trials, which aim to compare the TSI dual-therapy regimen versus the standards of care in each indication,” said Alexis Wallace, MScEng, MBA, TSI co-founder and CEO. “We have fielded inquiries from potential pharmaceutical partners and look forward to continued dialogue as we progress our clinical programs to advance the treatment of stroke and heart attack.”
The Phase 2 studies in patients with ischemic stroke and MI follow a Phase 1 study performed at the Centre for Human Drug Research (CHDR), in Leiden, The Netherlands, led by Prof. Koos Burggraaf, MD, PhD, that confirmed the safety and tolerability of TSI’s bio-inspired treatment* regimen in healthy volunteers (n=26).
Both ischemic stroke and heart attack are triggered by a blood clot. To restore blood flow, the principal pharmacological treatment today consists of dissolving the clot, or thrombolysis, as quickly as possible by infusing a large dose of a single natural enzyme called tPA. Studies have shown, however, that natural thrombolysis is achieved by a sequence of tPA plus a second enzyme called proUK. “This system’s function is analogous to that of a car engine, where tPA is akin to the starter and proUK is the fuel,” says Prof. Victor Gurewich, MD, TSI co-founder and scientific director. “As with this example, dissolving a blood clot effectively and safely requires both tPA and proUK in sequence.”
*Inspired by or based on biological structures or processes.
About Thrombolytic Science
Thrombolytic Science, LLC (TSI) is a privately-held vascular health and biotechnology company leading development of a next-generation, life-saving therapy to transform traditional medical approaches for treating blood clots caused by ischemic stroke and heart attacks – interventions that have not changed in decades. The company’s vision is to bring clot-dissolving therapy directly to the patient quickly, especially following an ischemic stroke, rather than having a patient wait to get to a hospital. TSI's dual, sequential thrombolytic regimen was established by research in the laboratory of Prof. Victor Gurewich, MD, Harvard Medical School. For more information, follow TSI on Twitter @ThrombolyticSci and visit tsillc.net.
Reba Auslander, RAliance Communications